Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Biogen Idec Stories

2013-09-09 08:26:40

--Biogen Idec and Isis to leverage antisense technology to accelerate discovery and development of novel therapies-- WESTON, Mass. and CARLSBAD, Calif., Sept. 9, 2013 /PRNewswire/ -- Biogen Idec (NASDAQ: BIIB) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the companies have entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines Biogen Idec's expertise in neurology with Isis'...

2013-09-08 23:01:44

Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. Dallas, Texas (PRWEB) September 08, 2013 The global multiple sclerosis therapeutics market has the potential to grow to a value of $17.9 billion by 2019. The market is currently led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period...

2013-09-03 08:29:14

Novel Disease-Modifying Therapies and Reformulations Will Experience Distinct Positioning and Market Access Challenges, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed neurologists consider Biogen Idec's Tecfidera to be a breakthrough in the treatment of multiple sclerosis (MS),...

2013-08-28 08:27:16

Patient Share for Tecfidera Has Doubled Among Relapsing-Remitting MS Patients Compared With Two Months Ago, According to a New Report from BioTrends Research Group EXTON, Pa., Aug. 28, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that patient share for Biogen Idec's Tecfidera among relapsing-remitting multiple sclerosis (RR-MS) patients treated with disease modifying therapy (DMT)...

2013-08-22 23:21:27

Leading provider of smart data solutions for the pharmaceutical industry to speak and exhibit at the conference. BOSTON (PRWEB) August 22, 2013 Cambridge Semantics, leading provider of smart data solutions for the pharmaceutical industry, today announced its participation in the 2013 Pharma CI Conference & Exposition. Lee Feigenbaum, Vice President of Marketing and Technology for Cambridge Semantics, will present on pharma competitive intelligence (CI) solutions to automate data...

2013-08-22 20:22:08

Kindred Bio Appoints Dr. Stephen Sundlof, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as Senior Vice President of Regulatory Affairs SAN FRANCISCO, Aug. 22, 2013 /PRNewswire/ -- Kindred Biosciences, Inc. (Kindred Bio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs. Dr. Sundlof...

2013-08-14 08:30:23

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2013 U.S. prescription sales data for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and AstraZeneca's acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key tumor necrosis factor (TNF)...

2013-08-13 16:26:17

-'Road to the Clinic' Strategy On Track; Preparing for Clinical Development of RG-101 for HCV; Second microRNA Clinical Candidate to be Nominated by Year End - LA JOLLA, Calif., Aug. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended June 30, 2013 and provided a summary of recent corporate highlights. "The second...

2013-08-08 08:31:35

Biologic Agents, Including Rituxan and Benlysta, are Reserved for Moderate-to-Severe Cases of SLE, According to a New Report from BioTrends Research Group EXTON, Pa., Aug. 8, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that rheumatologists in the EU5 countries (France, Germany, Italy, Spain, United Kingdom) give Genentech/Biogen Idec's Rituxan and GlaxoSmithKline/Human Genome...

2013-08-07 08:30:31

CereKin(TM) (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis. SAN FRANCISCO, Aug. 7, 2013 /PRNewswire/ -- Kindred Biosciences, Inc. (Kindred Bio) announced today that it has initiated a pivotal clinical trial for CereKin(TM) (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of...